A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo

Abstract

BackgroundLong-term use of levodopa (l-dopa) is inevitably complicated with highly disabling fluctuations and drug-induced dyskinesias, which pose major challenges to the existing drug therapy of Parkinson’s disease.MethodsIn this study, we conducted a systematic review and meta-analysis to assess the efficacy of A2A receptor antagonists on reducing l-dopa-induced dyskinesias (LID).ResultsNine studies with a total of 152 animals were included in this meta-analysis. Total abnormal involuntary movements (AIM) score, locomotor activity, and motor disability were reported as outcome measures in 5, 5, and 3 studies, respectively. Combined standardized mean difference (SMD) estimates were calculated using a random-effects model. We pooled the whole data and found that, when compared to l-dopa alone, A2A receptor antagonists plus l-dopa treatment showed no effect on locomotor activity (SMD −0.00, 95% confidence interval (CI): −2.52 to 2.52, p = 1.0), superiority in improvement of motor disability (SMD −5.06, 95% CI: −9.25 to −0.87, p = 0.02) and more effective in control of AIM (SMD −1.82, 95% CI: −3.38 to −0.25, p = 0.02).ConclusionTo sum up, these results demonstrated that A2A receptor antagonists appear to have efficacy in animal models of LID. However, large randomized clinical trials testing the effects of A2A receptor antagonists in LID patients are always warranted.

Impact of Parkinson’s disease on the efficiency of masticatory cycles: Electromyographic analysis

“…One of the side effects of levodopa is dyskinesia (23), which may alter muscle activity and possibly the masticatory pattern. According to differences between patients and controls may be due to side effects of the treatment, not the disease.…”

Bayesian fluid prediction by decoupling both pore structure parameter and porosity

“…Evidently, relying solely on the prior probability distribution scheme is insufficient for eliminating the parameter correlations. To address this issue, an improved decorrelation method (Wang et al, 2017) is adopted to obtain parameters with the lowest possible correlation, which uses the variance matrix and two linear transformations based on Chen's previous work (Chen et al, 2007) to convert relevant data into "white data. "…”

Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease

“…88 This might indicate a benefit by additional A 1 R antagonism for the treatment of dyskinesia as hypothesized previously. 89,90 Although cotreatment of A 2A R antagonists with L-DOPA could not prevent the occurrence of dyskinesia, the incidence of LID might be reduced via lowering the effective dose of L-DOPA. 88, 91 Recently, it was reported that preladenant, in combination with the serotonin receptor agonist eltoprazine, attenuated LID without exacerbating the PD disability score in MPTP-treated macaques when administrated in a subthreshold dose of L-DOPA.…”